Group sequential trials - Revision history

Lawrence: /* Conclusion */

2025-06-04T01:31:39Z

Conclusion

← Older revision		Revision as of 01:31, 4 June 2025
Line 67:		Line 67:
	----		----

	See also: ~~[[Adaptive trials]];~~ [[Data Safety and Monitoring Board\|Data Safety and Monitoring Board (DSMB)]]; [[CONSORT]]		See also:[[Data Safety and Monitoring Board\|Data Safety and Monitoring Board (DSMB)]]; [[CONSORT]]

	----		----

Lawrence: /* Bibliography: */

2025-06-03T22:11:20Z

Bibliography:

← Older revision		Revision as of 22:11, 3 June 2025
Line 69:		Line 69:
	See also: [[Adaptive trials]]; [[Data Safety and Monitoring Board\|Data Safety and Monitoring Board (DSMB)]]; [[CONSORT]]		See also: [[Adaptive trials]]; [[Data Safety and Monitoring Board\|Data Safety and Monitoring Board (DSMB)]]; [[CONSORT]]

	~~== Bibliography: ==~~		----
	Parsons, N.R., Basu, J. & Stallard, N. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10870612/ Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementation.] ''BMC Med Res Methodol'' 24, 42 (2024).

	~~----~~		=== Bibliography ===

			# Pocock SJ. Group sequential methods in the design and [[analysis]] of clinical trials. ''Biometrika''. 1977;64(2):191–199.
			# O'Brien PC, Fleming TR. A [[multiple testing]] procedure for clinical trials. ''Biometrics''. 1979;35(3):549–556.
			# Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. CRC Press; 2000.
			# Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. Springer; 2006.
			# FDA. Guidance for Industry: Adaptive Designs for Clinical Trials of Drugs and Biologics. U.S. Food and Drug Administration; 2019. Includes discussion of group sequential approaches. Available from: https://www.fda.gov
			# Parsons, N.R., Basu, J. & Stallard, N. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10870612/ Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementation.] ''BMC Med Res Methodol'' 24, 42 (2024).
			----
	''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 01:33, 4 April 2025

2025-04-04T01:33:33Z

← Older revision		Revision as of 01:33, 4 April 2025
Line 52:		Line 52:

	* '''COVID-19 Vaccine Trials''': The Pfizer-BioNTech and Moderna trials used interim analyses to assess early efficacy and expedite emergency use authorization.		* '''COVID-19 Vaccine Trials''': The Pfizer-BioNTech and Moderna trials used interim analyses to assess early efficacy and expedite emergency use authorization.
	* '''ONTARGET Trial''': A cardiovascular study that applied sequential monitoring for safety and efficacy of antihypertensive treatments.		* '''[https://pubmed.ncbi.nlm.nih.gov/18378520/ ONTARGET Trial]''': A cardiovascular study that applied sequential monitoring for safety and efficacy of antihypertensive treatments.
	* '''Cancer Immunotherapy Trials''': Some trials evaluating checkpoint inhibitors were stopped early due to clear survival benefits over chemotherapy.		* '''Cancer Immunotherapy Trials''': Some trials evaluating checkpoint inhibitors were stopped early due to clear survival benefits over chemotherapy.

Lawrence at 01:30, 4 April 2025

2025-04-04T01:30:25Z

← Older revision		Revision as of 01:30, 4 April 2025
Line 72:		Line 72:
	Parsons, N.R., Basu, J. & Stallard, N. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10870612/ Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementation.] ''BMC Med Res Methodol'' 24, 42 (2024).		Parsons, N.R., Basu, J. & Stallard, N. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10870612/ Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementation.] ''BMC Med Res Methodol'' 24, 42 (2024).

	~~<nowiki>~~----~~</nowiki>~~		----

	~~<nowiki>~~''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''~~</nowiki>~~		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 01:29, 4 April 2025

2025-04-04T01:29:11Z

Lawrence at 01:25, 4 April 2025

2025-04-04T01:25:00Z

← Older revision		Revision as of 01:25, 4 April 2025
Line 67:		Line 67:
	----		----

	See also:		See also: [[Adaptive trials]]; [[Data Safety and Monitoring Board\|Data Safety and Monitoring Board (DSMB)]]; [[CONSORT]]
	* [[Adaptive trials]]
	* [[Data Safety and Monitoring Board (DSMB)]]		== Bibliography: ==
	* [[~~O’Brien-Fleming Method~~]]		Parsons, N.R., Basu, J. & Stallard, N. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10870612/ Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementation.] ''BMC Med Res Methodol'' 24, 42 (2024).
	* [~~[Pocock Method]~~]
	* [[CONSORT]]		<nowiki>----</nowiki>

			<nowiki>''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''</nowiki>

Lawrence at 19:48, 26 March 2025

2025-03-26T19:48:12Z

← Older revision		Revision as of 19:48, 26 March 2025
Line 8:		Line 8:

	To guide early stopping decisions, the trial defines stopping boundaries:		To guide early stopping decisions, the trial defines stopping boundaries:
	* An efficacy boundary allows early termination if the treatment effect is significantly positive.		* An '''efficacy boundary''' allows early termination if the treatment effect is significantly positive.
	* A futility boundary is used when interim data suggest the intervention is unlikely to demonstrate benefit.		* A '''futility boundary''' is used when interim data suggest the intervention is unlikely to demonstrate benefit.
	* A safety boundary protects participants if unexpected adverse events emerge.		* A '''safety boundary''' protects participants if unexpected adverse events emerge.

	An independent Data Monitoring Committee (DMC) is responsible for reviewing interim data and recommending whether to stop, modify, or continue the trial based on the pre-specified criteria. Since multiple interim analyses increase the risk of Type I error (false positives), statistical adjustments must be made to control the overall significance level. Common adjustment methods include the O’Brien-Fleming and Pocock approaches.		An independent Data Monitoring Committee (DMC) is responsible for reviewing interim data and recommending whether to stop, modify, or continue the trial based on the pre-specified criteria. Since multiple interim analyses increase the risk of Type I error (false positives), statistical adjustments must be made to control the overall significance level. Common adjustment methods include the O’Brien-Fleming and Pocock approaches.
Line 68:		Line 68:

	See also:		See also:
	* [[Adaptive ~~trial designs~~]]		* [[Adaptive trials]]
	* [[Data Safety and Monitoring Board (DSMB)]]		* [[Data Safety and Monitoring Board (DSMB)]]
	* [[O’Brien-Fleming Method]]		* [[O’Brien-Fleming Method]]
	* [[Pocock Method]]		* [[Pocock Method]]
	* [[CONSORT]]		* [[CONSORT]]

Lawrence: Created page with "= Group sequential trials = A '''Group Sequential Trial''' is an adaptive randomized controlled trial (RCT) design that incorporates pre-planned interim analyses at defined time points before the trial concludes. This approach enables researchers to stop the trial early for efficacy, futility, or safety concerns. By doing so, group sequential designs can conserve resources, minimize participant exposure to ineffective treatments, and accelerate regulatory decision-makin..."

2025-03-26T19:46:43Z

Created page with "= Group sequential trials = A '''Group Sequential Trial''' is an adaptive randomized controlled trial (RCT) design that incorporates pre-planned interim analyses at defined time points before the trial concludes. This approach enables researchers to stop the trial early for efficacy, futility, or safety concerns. By doing so, group sequential designs can conserve resources, minimize participant exposure to ineffective treatments, and accelerate regulatory decision-makin..."

New page

= Group sequential trials =

A '''Group Sequential Trial''' is an adaptive randomized controlled trial (RCT) design that incorporates pre-planned interim analyses at defined time points before the trial concludes. This approach enables researchers to stop the trial early for efficacy, futility, or safety concerns. By doing so, group sequential designs can conserve resources, minimize participant exposure to ineffective treatments, and accelerate regulatory decision-making when a treatment is clearly beneficial.

== Key Features ==

A hallmark of group sequential trials is the inclusion of **pre-specified interim analyses**, typically scheduled after a certain percentage of participants have completed follow-up—such as at 25%, 50%, and 75% of the total sample. These interim checks provide opportunities to assess whether the trial should continue as planned or stop early.

To guide early stopping decisions, the trial defines **stopping boundaries**:
* An **efficacy boundary** allows early termination if the treatment effect is significantly positive.
* A **futility boundary** is used when interim data suggest the intervention is unlikely to demonstrate benefit.
* A **safety boundary** protects participants if unexpected adverse events emerge.

An independent **Data Monitoring Committee (DMC)** is responsible for reviewing interim data and recommending whether to stop, modify, or continue the trial based on the pre-specified criteria. Since multiple interim analyses increase the risk of Type I error (false positives), **statistical adjustments** must be made to control the overall significance level. Common adjustment methods include the O’Brien-Fleming and Pocock approaches.

== Advantages of Group Sequential Trials ==

Group sequential designs offer several important benefits. From an ethical standpoint, they minimize unnecessary exposure to ineffective or harmful treatments. They also allow for **faster decision-making**, potentially accelerating access to life-saving interventions.

These trials are **resource-efficient**, as stopping early for futility avoids the costs of completing a trial with little chance of success. Regular interim monitoring also enhances **patient safety**, allowing early identification of severe adverse effects.

== Stopping Rules ==

The following table summarizes common stopping rules used in group sequential designs:

{| class="wikitable"
! Stopping Rule !! When Applied !! Purpose
|-
| Early Stopping for Efficacy || When interim results show strong treatment effects || Enables faster access to effective treatments
|-
| Stopping for Futility || When the treatment is unlikely to demonstrate benefit || Prevents unnecessary continuation of the trial
|-
| Stopping for Safety || When a treatment causes serious adverse effects || Protects participants from harm
|}

== Common Statistical Methods ==

Group sequential trials rely on specialized statistical methods to maintain trial integrity while allowing multiple “looks” at the data.

'''O’Brien-Fleming Method:'''
This approach uses very stringent stopping rules in early stages, making it conservative in detecting early treatment effects. It is suitable when early stopping must be strongly justified, such as in life-saving interventions.

'''Pocock Method:'''
The Pocock approach uses a consistent boundary across all interim analyses. It offers a greater chance of stopping early and is useful in situations where cost savings or logistical simplicity are important.

'''Haybittle-Peto Rule:'''
This method sets a simple p-value threshold (e.g., p < 0.001) for early stopping. Though less statistically efficient, it has been used in large trials, particularly in cardiology and oncology.

== Examples of Group Sequential Trials ==

Several prominent trials have successfully applied group sequential designs:

* '''COVID-19 Vaccine Trials''': The Pfizer-BioNTech and Moderna trials used interim analyses to assess early efficacy and expedite emergency use authorization.
* '''ONTARGET Trial''': A cardiovascular study that applied sequential monitoring for safety and efficacy of antihypertensive treatments.
* '''Cancer Immunotherapy Trials''': Some trials evaluating checkpoint inhibitors were stopped early due to clear survival benefits over chemotherapy.

== Challenges and Limitations ==

While group sequential trials offer clear advantages, they also present challenges. One concern is the **risk of premature stopping**, especially when early decisions are based on small sample sizes. This can result in overestimating treatment effects or missing long-term outcomes.

The design requires **complex statistical planning**, including appropriate error control for repeated analyses. It also raises **ethical dilemmas**, particularly when trials are stopped for futility despite the potential for delayed treatment benefits that could have emerged with longer follow-up.

== Conclusion ==

Group Sequential Trials are a powerful and flexible tool in clinical research. They allow for ethical and efficient trial conduct by enabling early stopping based on pre-defined criteria for efficacy, futility, or safety. When properly designed and monitored, these trials can accelerate therapeutic development while protecting participants and conserving resources.

----

See also:
* [[Adaptive trial designs]]
* [[Data Safety and Monitoring Board (DSMB)]]
* [[O’Brien-Fleming Method]]
* [[Pocock Method]]
* [[CONSORT]]

← Older revision		Revision as of 01:29, 4 April 2025
Line 5:		Line 5:
	== Key Features ==		== Key Features ==

	A hallmark of group sequential trials is the inclusion of pre-specified interim analyses, typically scheduled after a certain percentage of participants have completed follow-up—such as at 25%, 50%, and 75% of the total sample. These interim checks provide opportunities to assess whether the trial should continue as planned or stop early.		A hallmark of group sequential trials is the inclusion of '''pre-specified interim analyses''', typically scheduled after a certain percentage of participants have completed follow-up—such as at 25%, 50%, and 75% of the total sample. These interim checks provide opportunities to assess whether the trial should continue as planned or stop early.

	To guide early stopping decisions, the trial defines stopping boundaries:		To guide early stopping decisions, the trial defines '''stopping boundaries''':
	* An '''efficacy boundary''' allows early termination if the treatment effect is significantly positive.		* An '''efficacy boundary''' allows early termination if the treatment effect is significantly positive.
	* A '''futility boundary''' is used when interim data suggest the intervention is unlikely to demonstrate benefit.		* A '''futility boundary''' is used when interim data suggest the intervention is unlikely to demonstrate benefit.
	* A '''safety boundary''' protects participants if unexpected adverse events emerge.		* A '''safety boundary''' protects participants if unexpected adverse events emerge.

	An independent Data Monitoring Committee (DMC) is responsible for reviewing interim data and recommending whether to stop, modify, or continue the trial based on the pre-specified criteria. Since multiple interim analyses increase the risk of Type I error (false positives), statistical adjustments must be made to control the overall significance level. Common adjustment methods include the O’Brien-Fleming and Pocock approaches.		An independent [[Data Safety and Monitoring Board]] is responsible for reviewing interim data and recommending whether to stop, modify, or continue the trial based on the pre-specified criteria. Since multiple interim analyses increase the risk of Type I error (false positives), '''statistical adjustments''' must be made to control the overall significance level. Common adjustment methods include the O’Brien-Fleming and Pocock approaches.

	== Advantages of Group Sequential Trials ==		== Advantages of Group Sequential Trials ==

	Group sequential designs offer several important benefits. From an ethical standpoint, they minimize unnecessary exposure to ineffective or harmful treatments. They also allow for faster decision-making, potentially accelerating access to life-saving interventions.		Group sequential designs offer several important benefits. From an ethical standpoint, they minimize unnecessary exposure to ineffective or harmful treatments. They also allow for '''faster decision-making''', potentially accelerating access to life-saving interventions.

	These trials are resource-efficient, as stopping early for futility avoids the costs of completing a trial with little chance of success. Regular interim monitoring also enhances patient safety, allowing early identification of severe adverse effects.		These trials are '''resource-efficient''', as stopping early for futility avoids the costs of completing a trial with little chance of success. Regular interim monitoring also enhances '''patient safety''', allowing early identification of severe adverse effects.

	== Stopping Rules ==		== Stopping Rules ==
Line 57:		Line 57:
	== Challenges and Limitations ==		== Challenges and Limitations ==

	While group sequential trials offer clear advantages, they also present challenges. One concern is the risk of premature stopping, especially when early decisions are based on small sample sizes. This can result in overestimating treatment effects or missing long-term outcomes.		While group sequential trials offer clear advantages, they also present challenges. One concern is the '''risk of premature stopping''', especially when early decisions are based on small sample sizes. This can result in overestimating treatment effects or missing long-term outcomes.

	The design requires complex statistical planning, including appropriate error control for repeated analyses. It also raises ethical dilemmas, particularly when trials are stopped for futility despite the potential for delayed treatment benefits that could have emerged with longer follow-up.		The design requires '''complex statistical planning''', including appropriate error control for repeated analyses. It also raises '''ethical dilemmas''', particularly when trials are stopped for futility despite the potential for delayed treatment benefits that could have emerged with longer follow-up.

	== Conclusion ==		== Conclusion ==